8-Nitro-2-tetralone | 909095-48-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 8-Nitro-2-tetralone
• 英文别名: 8-nitro-3,4-dihydro-1H-naphthalen-2-one
• CAS: 909095-48-3
• 化学式: C10H9NO3
• 分子量: 191.18
• InChiKey: VVKOGCRGSOMTDD-UHFFFAOYSA-N

物化性质

• 沸点：
  357.8±42.0 °C(Predicted)
• 密度：
  1.322±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  62.9
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] NEW AMINOTETRALINE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'AMINOTÉTRALINE
  申请人：GMEINER PETER

  公开号：WO2011076708A1

  公开（公告）日：2011-06-30

  The present application relates to compounds of formula (I): and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds in producing medicaments for the treatment of various diseases and conditions, such as of the central nervous system.

  本申请涉及以下式（I）的化合物：及其药学上可接受的盐和溶剂，其中取代基如本文所定义，含有这种化合物的组合物以及利用这种化合物生产用于治疗各种疾病和症状的药物，如中枢神经系统疾病。
• New aminotetraline derivatives
  申请人：Gmeiner, Peter

  公开号：EP2338873A1

  公开（公告）日：2011-06-29

  The present application relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds in producing medicaments for the treatment of various diseases and conditions, such as of the central nervous system.

  本申请涉及式（I）化合物及其药学上可接受的盐和溶剂合物，其中取代基如本文所定义，含有这种化合物的组合物以及利用这种化合物制备治疗各种疾病和病情的药物，例如中枢神经系统疾病和病情。
• Tetradydro-Naphthalene And Urea Derivatives
  申请人：Bouchon Axel

  公开号：US20080045546A1

  公开（公告）日：2008-02-21

  This invention relates to tetrahydro-naphthalene and urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene and urea derivatives of the present invention have vanilloid receptor (VR1) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).

  本发明涉及四氢萘和脲衍生物及其盐，其作为制药制剂的活性成分具有vanilloid受体（VR1）拮抗活性，可用于预防和治疗与VR1活性相关的疾病，特别是用于治疗泌尿系统疾病或障碍，如膀胱过度活动（过度活动膀胱），尿失禁，神经源性膀胱过度活动（膀胱过度反射），特发性膀胱过度活动（膀胱不稳定），良性前列腺增生和下尿路症状；慢性疼痛，神经病性疼痛，术后疼痛，类风湿性关节炎疼痛，神经痛，神经病，疼痛，神经损伤，缺血，神经退行性疾病，中风以及哮喘和慢性阻塞性肺（或气道）疾病（COPD）等炎症性疾病。
• NEW AMINOTETRALINE DERIVATIVES
  申请人：Gmeiner Peter

  公开号：US20120277262A1

  公开（公告）日：2012-11-01

  The present application relates to compounds of formula (I): and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds in producing medicaments for the treatment of various diseases and conditions, such as of the central nervous system.

  本申请涉及式(I)的化合物及其药学上可接受的盐和溶剂化合物，其中取代基如此定义，含有这种化合物的组合物以及在制备治疗各种疾病和病症的药物中使用这种化合物的用途，例如中枢神经系统的疾病和病症。
• AMINOTETRALINE DERIVATIVES
  申请人：Gmeiner Peter

  公开号：US20130331429A1

  公开（公告）日：2013-12-12

  The present application relates generally to amino tetraline derivative compounds and methods of use, specifically, embodiments including compounds of formula (I) described herein, pharmaceutically acceptable salts and solvates. More specifically, this application relates to amino tetraline derivative compounds and uses of such compounds producing medicaments for the treatment of various disease and conditions including movement disorders and disorders of the central nervous system.

  本申请涉及氨基四氢萘衍生物化合物及其使用方法，具体包括本文所述的式（I）化合物、药学上可接受的盐和溶剂的实施方式。更具体地说，本申请涉及氨基四氢萘衍生物化合物及其使用，用于制备治疗各种疾病和病症的药物，包括运动障碍和中枢神经系统疾病和病症。